berberine/Finding
One finding, on its own
A single claim from the graph, with the evidence strength computed from its study, the sentence it was drawn from, and the paper. This address does not change.
Inhibits CYP2C9
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Finding“In addition, losartan/E-3174 ratio doubled (P<0.01) after BBR administration, indicating a decrease in CYP2C9 activity.”
Quoted verbatim from Repeated administration of berberine inhibits cytochromes P450 in humans.. - Study
- crossover
- Duration
- 14 days
- Dose
- berberine 300 mg three times daily orally for 14 days versus placebo; losartan 30 mg probe
- Population
- Healthy Chinese male volunteers, randomised two-phase crossover with 4-week washout; CYP2C9 activity read from the 0 to 8 h losartan to E-3174 ratio (in vivo probe)
Repeated administration of berberine inhibits cytochromes P450 in humans.2012PMID:21870106Permalink
Keep reading
- Everything the graph holds on berberine
- Every compound studied against CYP2C9
- How to read the evidence strength and the marks
To cite this finding: https://catalystproject.ai/e/01M456WJZJWK4B4AW7A4D8FQRM